

CORDLIFE GROUP LIMITED
(Company Registration No.: 200102883E)
(Incorporated in the Republic of Singapore)

RECEIPT OF NOTICE FROM THE ASSOCIATION FOR THE ADVANCEMENT OF BLOOD & BIOTHERAPIES

The Board of Directors of Cordlife Group Limited (the "**Company**", and together with its subsidiaries, the "**Group**") refers to its announcements dated 30 November 2023, 5 December 2023 and 7 December 2023 in relation to, among others, the receipt of the notice from the Ministry of Health (the "**MOH**") and the updates on its accreditations with the Association for the Advancement of Blood & Biotherapies ("**AABB**").

The Company wishes to inform that it has received a notice from AABB informing the Company that AABB has withdrawn the Company's AABB accreditation for cord blood activities – collection, processing, storage and distribution.

Upon AABB's request in June 2024, the Company had provided an update of the MOH's notice to the Company to stop the collection, testing, processing and/or storage of any new cord blood for up to an additional three (3) months with effect on and from 15 June 2024 or unless sooner approved by the Director-General of Health.

AABB has notified the Company that the AABB can accredit the Company only after the MOH permits the Company to resume its business and the Company has fully resolved all quality issues and has several months of records available for on-site inspection. AABB has also informed the Company in its notice that the following are important considerations behind its decision:

- At present, the continued closure of the Company's cord blood banking services makes it impossible for AABB to identify non-conforming products, processes and events, as well as successful implementation of corrective measures supporting the AABB Accreditation Standards;
- AABB understands that the Company's priority must be to ensure any MOH citations are corrected, mitigated, and assessed for risk to protect the safety of patients and products; and
- AABB looks forward to working with the Company, and hopes the Company will seek accreditation once the MOH reinstates the Company's operations. If an application is made, the Company will follow the same accreditation process with a self-assessment followed by an on-site evaluation of the efficacy of the Company's quality management system.

As stated previously, the Company has been making efforts towards implementing appropriate rectification measures to address all areas of non-compliance identified by the MOH and to fulfil all requirements and to resume operations as soon as possible. Upon the receipt of approval from the MOH to resume operations, the Company will evaluate the feasibility of seeking AABB accreditation at a suitable time.

The Company does not expect that the withdrawal of the Company's AABB accreditation will result in any material impact to the Company's ability to continue its business operations and/or the financial performance of the Group for the financial year ending 31 December 2024.

In the meantime, shareholders of the Company and potential investors should exercise caution when dealing in the shares of the Company. They should consult their stockbrokers, bank managers, solicitors, or other professional advisers if they have any doubt about the actions they should take.

The Company will update its shareholders and the investing public, if there are any material developments, in accordance with the requirements of the SGX-ST listing rules.

By order of the Board

CORDLIFE GROUP LIMITED

Sharon Lim Siew Choo

Goh Xun Er

Company Secretaries

15 August 2024